Reference : Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with ...
Scientific journals : Article
Human health sciences : Immunology & infectious disease
Human health sciences : Oncology
http://hdl.handle.net/2268/77376
Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with stage IV hypopharyngeal carcinoma.
English
Ernoux-Neufcoeur, P. [> > > >]
Arafa, M. mailto [> > > >]
Decaestecker, C. [> > > >]
Duray, A. [> > > >]
Remmelink, M. [> > > >]
Leroy, X. [> > > >]
Herfs, Michael mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques >]
Somja, Joan mailto [Centre Hospitalier Universitaire de Liège - CHU > > Anatomie pathologique >]
Depuydt, C. E. [> > > >]
Delvenne, Philippe mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques >]
Saussez, S. mailto [> > Laboratory of Anatomy, Faculty of Medicine and Pharmacy, University of Mons, Pentagone 2A–Avenue du Champ de Mars, 6, B-7000 Mons, Belgium > > >]
Jan-2011
Journal of Cancer Research & Clinical Oncology
Springer Verlag
137
1
173-81
Yes (verified by ORBi)
International
0171-5216
Berlin
Germany
[en] PURPOSE: We examined p16, p21 and p53 expression in combination with the presence of human papillomavirus (HPV) DNA as molecular markers to predict survival in patients with stage IV hypopharyngeal squamous cell carcinoma (HSCC). METHODS: Paraffin-embedded tumours from HSCC patients (n = 75) were evaluated for p16, p21 and p53 expression by immunohistochemistry. HPV DNA was detected by GP5+/6+ consensus PCR and subsequent genotyping by E6/E7 type-specific PCR for HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68. RESULTS: Among the 61 specimens that tested positive for the beta-globin, HPV typing identified 50 patients with high-risk (hr) HPV types. HPV 16E7 DNA was detected in 74% (37 cases) of these specimens. Twelve patients were found to be infected with multiple HPV types. However, the presence of hrHPV DNA was not found to correlate with the proportion of disease-free patients. The 5-year disease-free survival rate was 73% in p53- tumours versus 48% in p53+ tumours (P = 0.008). CONCLUSION: In our series of patients with stage IV HSCC, the hrHPV+ subgroup had a similar prognosis (in terms of recurrence risk) as the HPV- subgroup. p53 overexpression was associated with a worse prognosis.
Giga-Cancer
Researchers
http://hdl.handle.net/2268/77376
10.1007/s00432-010-0871-2

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Ernoux 2010.pdfPublisher postprint470.2 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.